| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 42.708 | 47.429 | 47.368 | 32.730 | 36.434 | 41.572 | 52.260 | 56.803 | 60.153 | 57.460 |
| Total Income - EUR | 42.722 | 47.449 | 47.379 | 32.863 | 36.435 | 41.917 | 52.262 | 56.805 | 60.155 | 57.463 |
| Total Expenses - EUR | 28.872 | 27.971 | 29.880 | 26.588 | 31.185 | 27.255 | 25.667 | 32.011 | 33.496 | 24.527 |
| Gross Profit/Loss - EUR | 13.850 | 19.478 | 17.499 | 6.275 | 5.250 | 14.662 | 26.595 | 24.795 | 26.659 | 32.936 |
| Net Profit/Loss - EUR | 12.569 | 18.530 | 17.015 | 5.948 | 4.886 | 14.246 | 26.073 | 24.227 | 26.058 | 31.213 |
| Employees | 0 | 3 | 4 | 4 | 4 | 3 | 3 | 2 | 2 | 2 |
Check the financial reports for the company - Almiclinic Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 5.504 | 4.405 | 3.304 | 2.573 | 0 | 721 | 705 | 707 | 20.288 | 14.935 |
| Current Assets | 19.470 | 26.059 | 28.687 | 34.206 | 41.688 | 44.010 | 57.275 | 28.152 | 28.378 | 20.063 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 827 | 429 | 761 | 912 | 807 | 1.490 | 2.667 | 4.254 | 2.239 | 10.739 |
| Cash | 18.643 | 25.630 | 27.926 | 33.294 | 40.881 | 42.520 | 54.608 | 23.899 | 26.139 | 9.324 |
| Shareholders Funds | 21.543 | 28.719 | 29.924 | 33.174 | 35.311 | 38.344 | 55.278 | 24.276 | 46.216 | 31.261 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 3.431 | 1.744 | 2.067 | 3.605 | 6.377 | 6.388 | 2.702 | 4.584 | 2.450 | 3.737 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Almiclinic Srl